70 related articles for article (PubMed ID: 7684858)
1. Empirical chemotherapy for adenocarcinoma of unknown primary tumor site.
Sporn JR; Greenberg BR
Semin Oncol; 1993 Jun; 20(3):261-7. PubMed ID: 7684858
[TBL] [Abstract][Full Text] [Related]
2. Poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary tumor site.
Hainsworth JD; Greco FA
Semin Oncol; 1993 Jun; 20(3):279-86. PubMed ID: 8503024
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant and neoadjuvant therapy for gastric cancer.
Kelsen DP
Semin Oncol; 1996 Jun; 23(3):379-89. PubMed ID: 8658222
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
5. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
[TBL] [Abstract][Full Text] [Related]
6. Carcinoma of unknown primary site.
Greco FA; Burris HA; Erland JB; Gray JR; Kalman LA; Schreeder MT; Hainsworth JD
Cancer; 2000 Dec; 89(12):2655-60. PubMed ID: 11135228
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
8. One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1997 Dec; 24(6 Suppl 19):S19-101-S19-105. PubMed ID: 9427278
[TBL] [Abstract][Full Text] [Related]
9. Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy.
Greco FA; Hainsworth JD
Semin Oncol; 1994 Oct; 21(5 Suppl 12):77-82. PubMed ID: 7992071
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary.
Horlings HM; van Laar RK; Kerst JM; Helgason HH; Wesseling J; van der Hoeven JJ; Warmoes MO; Floore A; Witteveen A; Lahti-Domenici J; Glas AM; Van't Veer LJ; de Jong D
J Clin Oncol; 2008 Sep; 26(27):4435-41. PubMed ID: 18802156
[TBL] [Abstract][Full Text] [Related]
11. Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
Bavisotto LM; Patel NH; Althaus SJ; Coldwell DM; Nghiem HV; Thompson T; Storer B; Thomas CR
Clin Cancer Res; 1999 Jan; 5(1):95-109. PubMed ID: 9918207
[TBL] [Abstract][Full Text] [Related]
12. A phase II evaluation of high dose cisplatin and etoposide in patients with advanced esophageal adenocarcinoma.
Spiridonidis CH; Laufman LR; Jones JJ; Gray DJ; Cho CC; Young DC
Cancer; 1996 Nov; 78(10):2070-7. PubMed ID: 8918399
[TBL] [Abstract][Full Text] [Related]
13. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
14. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
15. Gynecological malignancies.
Schaebler DL; Schilder RJ; Young RC
Cancer Chemother Biol Response Modif; 1996; 16():564-91. PubMed ID: 8639401
[TBL] [Abstract][Full Text] [Related]
16. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
17. A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
Park YH; Ryoo BY; Choi SJ; Yang SH; Kim HT
Jpn J Clin Oncol; 2004 Nov; 34(11):681-5. PubMed ID: 15613558
[TBL] [Abstract][Full Text] [Related]
18. Curative and palliative aspects of regional chemotherapy in combination with surgery.
Müller H; Hilger R
Support Care Cancer; 2003 Jan; 11(1):1-10. PubMed ID: 12527948
[TBL] [Abstract][Full Text] [Related]
19. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.
Fishman PN; Pond GR; Moore MJ; Oza A; Burkes RL; Siu LL; Feld R; Gallinger S; Greig P; Knox JJ
Am J Clin Oncol; 2006 Jun; 29(3):225-31. PubMed ID: 16755174
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment in metastatic adenocarcinoma of unknown primary tumour.
Taal BG; Veenhof CH; Blijham GH; Neijt JP
Neth J Med; 1988 Apr; 32(3-4):204-11. PubMed ID: 3283582
[No Abstract] [Full Text] [Related]
[Next] [New Search]
